-
Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC
04 Aug 2025 20:59 GMT
… assistant professor of Medicine at Harvard Medical School, thoracic … and TROPION-Lung01 trials, which collectively showed … for patients receiving pemetrexed who have eye … drugs [for], giving steroids, and monitoring for improvement before starting [treatment …
-
Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan
01 Aug 2025 09:48 GMT
… (TKI) treatment.
The open-label, randomised trial has enrolled … standard-of-care chemotherapy (pemetrexed/carboplatin), against … unmet medical need.”
LP-300 is an investigational drug … deserve! The Clinical Trials Arena Excellence Awards celebrate …
-
Biomednewsbreaks - Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment For Phase 2 HARMONIC Trial In Japan
31 Jul 2025 18:49 GMT
… The trial evaluates LP-300 with carboplatin and pemetrexed in … and timeline of oncology drug discovery and development. Our … multiple Phase 1 clinical trials. Our AI-driven … the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) …
-
Strategic Advances in EGFR+ NSCLC: Navigating Evolving Treatment Paths With Dato-DXd
28 Jul 2025 19:41 GMT
… Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer … osimertinib, commonly utilizing carboplatin and pemetrexed in conjunction with osimertinib. This … recent FDA approval, is Dato-DXd.
For patients who commence treatment with …
-
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
28 Jul 2025 21:19 GMT
… Drug Administration (FDA) has approved SEPHIENCE™ (sepiapterin) for the treatment … trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and … clinically differentiated medicines for children … with any pharmaceutical under development, …
-
Understanding Underlying Resistance Mechanisms is Vital for Guiding Treatment Selection Post-Osimertinib in EGFR+ NSCLC
25 Jul 2025 21:14 GMT
… -based treatment, including the phase 3 MARIPOSA-2 trial (NCT04988295 … Stanford University School of Medicine, deputy director and … as carboplatin plus pemetrexed with or without … ;www.fda.gov/drugs/;resources-information-approved-drugs/fda-grants- …
-
High-Risk Features Could Guide Treatment Intensification in First-Line EGFR-Mutated NSCLC
25 Jul 2025 21:14 GMT
…
“We currently have 3 FDA-approved [treatment] options: osimertinib, osimertinib … clinical professor of medicine at the University of … 3 MARIPOSA (NCT04487080) trials. The studies examined osimertinib … with or without platinum-pemetrexed. Presented at: 2024 …
-
AstraZeneca’s Tagrisso combo shows OS improvement in Phase III NSCLC trial
22 Jul 2025 15:53 GMT
… cycles, the treatment continued with Tagrisso alongside maintenance doses of pemetrexed, also … of the individual medicines.
According to the company, the trial recorded higher … you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation …
-
AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR─mutated advanced lung cancer
22 Jul 2025 04:57 GMT
… president for Translational Medicine and thoracic medical oncologist at Dana … in addition to prior trials showing survival benefits as … phase III trial in the 1st-line treatment of patients with … with the addition of chemotherapy (pemetrexed (500mg/m2) …
-
AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer
21 Jul 2025 22:08 GMT
… 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed … from the FLAURA2 Phase 3 trial showing Tagrisso (osimertinib) … established profiles of the individual medicines.
Adverse event (AE) … the FLAURA2 Phase 3 trial, Tagrisso plus chemotherapy is …